4D Molecular Therapeutics Inc
FDMT
Company Profile
Business description
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
Contact
5858 Horton Street
Suite 455
EmeryvilleCA94608
USAT: +1 510 505-2680
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
227
Stocks News & Analysis
stocks
Cheap Narrow Moat ASX share continues to face negative sentiment
Earnings growth fails to excite investors worried about AI disruption.
stocks
ASX energy giant remains cheap following record production
Impressive cost control and record production leads to higher dividend.
stocks
Strong results from cheap ASX share
The market responded favourably to results but shares still underpriced.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,359.00 | 50.70 | 0.54% |
| CAC 40 | 8,559.07 | 39.86 | 0.47% |
| DAX 40 | 25,175.94 | 189.69 | 0.76% |
| Dow JONES (US) | 49,479.32 | 304.82 | 0.62% |
| FTSE 100 | 10,806.41 | 125.82 | 1.18% |
| HKSE | 26,765.72 | 175.40 | 0.66% |
| NASDAQ | 23,154.91 | 291.23 | 1.27% |
| Nikkei 225 | 58,583.12 | 1,262.03 | 2.20% |
| NZX 50 Index | 13,525.58 | 6.73 | -0.05% |
| S&P 500 | 6,948.17 | 58.10 | 0.84% |
| S&P/ASX 200 | 9,128.30 | 44.20 | 0.49% |
| SSE Composite Index | 4,147.23 | 29.82 | 0.72% |